VIVUS

CA - CampbellBiotechnology

Website LinkedIn Careers Page

Focus: Small Molecules

VIVUS is a life sciences company focused on Small Molecules.

Metabolic Diseases Nephrology Oncology Neurology

Profile data last refreshed Yesterday

Open Jobs

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

8 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ULTRESA

Fibrosing Colonopathy

N/A

avanafil

Renal

Phase 1

Clinical Trials (1)

Help build intelligence for VIVUS

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

NCT01054261To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.

Phase 1

Phentermine and Topiramate

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT00768209A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment

Phase 1

200 mg Avanafil

Erectile Dysfunction

Phase 1

Clinical Trials (1)

NCT01095588Study the Effect of Avanafil on the Pharmacodynamics and Pharmacokinetics of Warfarin in Healthy Male Subjects

Phase 1

Tamsulosin and avanafil

Erectile Dysfunction

Phase 1

Clinical Trials (1)

NCT01100021Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin

Phase 1

Omeprazole

Erectile Dysfunction

Phase 1

Clinical Trials (1)

NCT01415128Compare the Pharmacokinetics of Omeprazole, Rosiglitazone, and Desipramine When Administered With Avanafil in Healthy Male Subjects

Phase 1

Ritonavir

Erectile Dysfunction

Phase 1

Clinical Trials (1)

NCT00770042To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil

Phase 1

avanafil and enalapril

Erectile Dysfunction

Phase 1

Clinical Trials (1)

NCT01117038Drug Interaction Study of Avanafil and Enalapril or Amlodipine

Phase 1

avanafil

Erectile Dysfunction

Phase 1

Clinical Trials (1)

NCT01054430To Assess the Safety of Avanafil in Healthy and Hepatically Impaired Male Subjects.

Phase 1

avanafil

Erectile Dysfunction

Phase 1

Clinical Trials (1)

NCT01054859A Phase I Crossover Study of the Hemodynamic Interactions of Avanafil & Alcohol in Healthy Male Subjects.

Phase 1

moxifloxacin

Erectile Dysfunction

Phase 1

Clinical Trials (1)

NCT00769041A Thorough EKG Safety Study of TA-1790 (Avanafil)

Phase 1

topiramate

Obesity

Phase 1

Clinical Trials (1)

NCT00518466Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults

Phase 1

Metformin, VI-0521, Sitagliptan, Probenecid

Obesity

Phase 1

Clinical Trials (1)

NCT00842400A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

Phase 1

VI-0521

Torsades de Pointes

Phase 1

Clinical Trials (1)

NCT00839891A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers

Phase 1

Avanafil

Healthy

Phase 1

Clinical Trials (1)

NCT01095601Assess the Effect of Food on Avanafil Pharmacokinetic (PK), to Compare 2 Oral Formulations of Avanafil,and Investigate Dose Proportionality in Healthy Male Subjects

Phase 1

TA-1790

Erectile Dysfunction

Phase 1

Clinical Trials (1)

NCT01616485Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo

Phase 1

Topirmate and Phentermine

Renal Impairment

Phase 1

Clinical Trials (1)

NCT00768404A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment

Phase 1

ethinyl estradiol, norethindrone, VI-0521

Healthy

Phase 1

Clinical Trials (1)

NCT00821496Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects

Phase 1

Testosterone Spray 5% and 1%

Hypoactive Sexual Desire Disorder

Phase 1

Clinical Trials (1)

NCT01096329A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®

Phase 1

avanafil 200mg

Avanfil ADME

Phase 1

Clinical Trials (1)

NCT00914511A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects

Phase 1

VI-0521

Sleep Apnea

Phase 1/2

Clinical Trials (1)

NCT00745251A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults

Phase 1/2

Phentermine/topiramate

Obesity

Phase 2

Clinical Trials (1)

NCT02301416Qsymia as an Adjunct to Surgical Therapy in the Superobese

Phase 2

VI-1121

Alzheimer's Disease

Phase 2

Clinical Trials (1)

NCT01428362VI-1121 for the Treatment Alzheimer's Disease

Phase 2

Phentermine/Topiramate

Diabetes

Phase 2

Clinical Trials (1)

NCT00600067A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults

Phase 2

VI-0521

Type 2 Diabetes Mellitus

Phase 2

Clinical Trials (1)

NCT00486291Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics

Phase 2

Topical alprostadil

Sexual Dysfunction, Physiological

Phase 2

Clinical Trials (1)

NCT00324948Topical Alprostadil for Female Sexual Arousal Disorder

Phase 2

VI-0609

Lymphoma

Phase 2

Clinical Trials (1)

NCT06915246A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

Phase 2

VI-0521

Overweight

Phase 2

Clinical Trials (1)

NCT00806260A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.

Phase 2

VI-0521

Diabetes

Phase 2

Clinical Trials (1)

NCT00737633Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults

Phase 2

Pancrelipase

Pancreatic Adenocarcinoma

Phase 2

Clinical Trials (1)

NCT04098237Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

Phase 2

placebo

Erectile Dysfunction

Phase 3

Clinical Trials (1)

NCT00809471Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)

Phase 3

avanafil

Erectile Dysfunction

Phase 3

Clinical Trials (1)

NCT00853606Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction

Phase 3

Placebo

Erectile Dysfunction

Phase 3

Clinical Trials (1)

NCT00895011Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy

Phase 3

VI-0521

Obesity

Phase 3

Clinical Trials (1)

NCT00554216Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults

Phase 3

VI-0521

Obesity

Phase 3

Clinical Trials (1)

NCT00563368A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults

Phase 3

placebo

Erectile Dysfunction

Phase 3

Clinical Trials (1)

NCT00790751Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED

Phase 3

VI-0521

Obesity

Phase 3

Clinical Trials (1)

NCT00553787Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions

Phase 3

VI-0521

Obesity

Phase 3

Clinical Trials (1)

NCT00796367A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)

Phase 3

VI-0521

Blood Pressure

Phase 4

Clinical Trials (1)

NCT05215418A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects

Phase 4

Qsymia

Obesity

Phase 4

Clinical Trials (1)

NCT02229214Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects